首页> Bioorganic & medicinal chemistry letters> Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.

导出原文传递

翻译打印收藏纠错

第一作者： Mark,Adams

第一单位： Medicinal Chemistry, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, United States.

作者： Mark,Adams ^[1] ; Toshitake,Kobayashi ^[2] ; J David,Lawson ^[3] ; Morihisa,Saitoh ^[2] ; Kenichiro,Shimokawa ^[2] ; Simone V,Bigi ^[1] ; Mark S,Hixon ^[4] ; Christopher R,Smith ^[1] ; Takayuki,Tatamiya ^[2] ; Masayuki,Goto ^[2] ; Joseph,Russo ^[5] ; Charles E,Grimshaw ^[3] ; Steven,Swann ^[1]

作者单位： Medicinal Chemistry, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, United States. ^[1] Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. ^[2] Computational Sciences and Crystallography, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, United States. ^[3] Global DMPK, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, United States. ^[4] CNS & Novel Target ID, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, United States. ^[5]

关键词 FBDD MAP Kinase Kinase 3 (MKK3)MAP Kinase Kinase 6 (MKK6)